S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Don't Become Another "Hold And Hope Disaster" (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
How He’s Maintained A Staggering 6-Year 97% Trading Win Rate (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
How He’s Maintained A Staggering 6-Year 97% Trading Win Rate (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Don't Become Another "Hold And Hope Disaster" (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
How He’s Maintained A Staggering 6-Year 97% Trading Win Rate (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
How He’s Maintained A Staggering 6-Year 97% Trading Win Rate (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Don't Become Another "Hold And Hope Disaster" (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
How He’s Maintained A Staggering 6-Year 97% Trading Win Rate (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
How He’s Maintained A Staggering 6-Year 97% Trading Win Rate (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Don't Become Another "Hold And Hope Disaster" (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
How He’s Maintained A Staggering 6-Year 97% Trading Win Rate (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
How He’s Maintained A Staggering 6-Year 97% Trading Win Rate (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself

Acasti Pharma Stock Price, News & Analysis (NASDAQ:ACST)

$2.05
-0.03 (-1.44%)
(As of 11/29/2023 ET)
Compare
Today's Range
$2.00
$2.10
50-Day Range
$1.75
$2.95
52-Week Range
$1.72
$5.05
Volume
13,162 shs
Average Volume
28,635 shs
Market Capitalization
$19.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.70

Acasti Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
617.1% Upside
$14.70 Price Target
Short Interest
Healthy
1.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Acasti Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1.25 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.44) to ($1.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

92nd out of 949 stocks

Pharmaceutical Preparations Industry

32nd out of 431 stocks


ACST stock logo

About Acasti Pharma Stock (NASDAQ:ACST)

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

ACST Stock Price History

ACST Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Acasti announces $7.5M private placement equity funding
Acasti Pharma: Reverse Stock Split To Become Effective July 10
Acasti Pharma Announces 1-for-6 Reverse Stock Split
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Recap: Acasti Pharma Q4 Earnings
Acasti Pharma's Earnings Outlook
H.C. Wainwright Keeps Their Buy Rating on Acasti Pharma (ACST)
See More Headlines
Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
11/29/2023
Next Earnings (Estimated)
2/13/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACST
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.70
High Stock Price Target
$15.00
Low Stock Price Target
$14.40
Potential Upside/Downside
+617.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-42,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$200,000.00
Book Value
$7.10 per share

Miscellaneous

Free Float
8,129,000
Market Cap
$19.27 million
Optionable
Not Optionable
Beta
1.34
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Prashant Kohli (Age 51)
    CEO & Director
    Comp: $358.41k
  • Mr. Brian D. Ford CPA (Age 64)
    CA, Interim Chief Financial Officer
    Comp: $379.35k
  • Dr. R. Loch MacDonald M.D. (Age 61)
    Ph.D., Member of Scientific Advisory Board & Chief Medical Officer
  • Mr. Amresh Kumar Ph.D. (Age 43)
    VP of Program Management
  • Ms. Carrie D'Andrea (Age 51)
    VP of Clinical Operations














ACST Stock Analysis - Frequently Asked Questions

Should I buy or sell Acasti Pharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACST shares.
View ACST analyst ratings
or view top-rated stocks.

What is Acasti Pharma's stock price target for 2024?

2 brokerages have issued twelve-month target prices for Acasti Pharma's stock. Their ACST share price targets range from $14.40 to $15.00. On average, they expect the company's stock price to reach $14.70 in the next twelve months. This suggests a possible upside of 617.1% from the stock's current price.
View analysts price targets for ACST
or view top-rated stocks among Wall Street analysts.

How have ACST shares performed in 2023?

Acasti Pharma's stock was trading at $3.0060 at the beginning of the year. Since then, ACST shares have decreased by 31.8% and is now trading at $2.05.
View the best growth stocks for 2023 here
.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 91,900 shares, a drop of 10.0% from the October 31st total of 102,100 shares. Based on an average daily trading volume, of 49,200 shares, the short-interest ratio is presently 1.9 days. Currently, 1.5% of the shares of the stock are sold short.
View Acasti Pharma's Short Interest
.

When is Acasti Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our ACST earnings forecast
.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) released its quarterly earnings results on Monday, November, 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.10.

When did Acasti Pharma's stock split?

Acasti Pharma shares reverse split before market open on Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).

How do I buy shares of Acasti Pharma?

Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACST) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -